

Biosimilars-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

<https://marketpublishers.com/r/B13EC501C72EN.html>

Date: February 2018

Pages: 138

Price: US\$ 3,680.00 (Single User License)

ID: B13EC501C72EN

Abstracts

Report Summary

Biosimilars-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Biosimilars industry, standing on the readers' perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of Biosimilars 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Biosimilars worldwide and market share by regions, with company and product introduction, position in the Biosimilars market

Market status and development trend of Biosimilars by types and applications

Cost and profit status of Biosimilars, and marketing status

Market growth drivers and challenges

The report segments the global Biosimilars market as:

Global Biosimilars Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)

Asia Pacific (China, Japan, India, Southeast Asia and Australia)

Latin America (Brazil, Argentina and Colombia)

Middle East and Africa

Global Biosimilars Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Antibody
Hormone
Growth Factors

Global Biosimilars Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Tumor
Diabetes
Cardiovascular
Hemophilia
Other

Global Biosimilars Market: Manufacturers Segment Analysis (Company and Product introduction, Biosimilars Sales Volume, Revenue, Price and Gross Margin):

Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Sun
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao

Ganlee
United Laboratories

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF BIOSIMILARS

- 1.1 Definition of Biosimilars in This Report
- 1.2 Commercial Types of Biosimilars
 - 1.2.1 Antibody
 - 1.2.2 Hormone
 - 1.2.3 Growth Factors
- 1.3 Downstream Application of Biosimilars
 - 1.3.1 Tumor
 - 1.3.2 Diabetes
 - 1.3.3 Cardiovascular
 - 1.3.4 Hemophilia
 - 1.3.5 Other
- 1.4 Development History of Biosimilars
- 1.5 Market Status and Trend of Biosimilars 2013-2023
 - 1.5.1 Global Biosimilars Market Status and Trend 2013-2023
 - 1.5.2 Regional Biosimilars Market Status and Trend 2013-2023

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of Biosimilars 2013-2017
- 2.2 Sales Market of Biosimilars by Regions
 - 2.2.1 Sales Volume of Biosimilars by Regions
 - 2.2.2 Sales Value of Biosimilars by Regions
- 2.3 Production Market of Biosimilars by Regions
- 2.4 Global Market Forecast of Biosimilars 2018-2023
 - 2.4.1 Global Market Forecast of Biosimilars 2018-2023
 - 2.4.2 Market Forecast of Biosimilars by Regions 2018-2023

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Sales Volume of Biosimilars by Types
- 3.2 Sales Value of Biosimilars by Types
- 3.3 Market Forecast of Biosimilars by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Global Sales Volume of Biosimilars by Downstream Industry
- 4.2 Global Market Forecast of Biosimilars by Downstream Industry

CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 5.1 North America Biosimilars Market Status by Countries
 - 5.1.1 North America Biosimilars Sales by Countries (2013-2017)
 - 5.1.2 North America Biosimilars Revenue by Countries (2013-2017)
 - 5.1.3 United States Biosimilars Market Status (2013-2017)
 - 5.1.4 Canada Biosimilars Market Status (2013-2017)
 - 5.1.5 Mexico Biosimilars Market Status (2013-2017)
- 5.2 North America Biosimilars Market Status by Manufacturers
- 5.3 North America Biosimilars Market Status by Type (2013-2017)
 - 5.3.1 North America Biosimilars Sales by Type (2013-2017)
 - 5.3.2 North America Biosimilars Revenue by Type (2013-2017)
- 5.4 North America Biosimilars Market Status by Downstream Industry (2013-2017)

CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 6.1 Europe Biosimilars Market Status by Countries
 - 6.1.1 Europe Biosimilars Sales by Countries (2013-2017)
 - 6.1.2 Europe Biosimilars Revenue by Countries (2013-2017)
 - 6.1.3 Germany Biosimilars Market Status (2013-2017)
 - 6.1.4 UK Biosimilars Market Status (2013-2017)
 - 6.1.5 France Biosimilars Market Status (2013-2017)
 - 6.1.6 Italy Biosimilars Market Status (2013-2017)
 - 6.1.7 Russia Biosimilars Market Status (2013-2017)
 - 6.1.8 Spain Biosimilars Market Status (2013-2017)
 - 6.1.9 Benelux Biosimilars Market Status (2013-2017)
- 6.2 Europe Biosimilars Market Status by Manufacturers
- 6.3 Europe Biosimilars Market Status by Type (2013-2017)
 - 6.3.1 Europe Biosimilars Sales by Type (2013-2017)
 - 6.3.2 Europe Biosimilars Revenue by Type (2013-2017)
- 6.4 Europe Biosimilars Market Status by Downstream Industry (2013-2017)

CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE,

MANUFACTURERS AND DOWNSTREAM INDUSTRY

7.1 Asia Pacific Biosimilars Market Status by Countries

7.1.1 Asia Pacific Biosimilars Sales by Countries (2013-2017)

7.1.2 Asia Pacific Biosimilars Revenue by Countries (2013-2017)

7.1.3 China Biosimilars Market Status (2013-2017)

7.1.4 Japan Biosimilars Market Status (2013-2017)

7.1.5 India Biosimilars Market Status (2013-2017)

7.1.6 Southeast Asia Biosimilars Market Status (2013-2017)

7.1.7 Australia Biosimilars Market Status (2013-2017)

7.2 Asia Pacific Biosimilars Market Status by Manufacturers

7.3 Asia Pacific Biosimilars Market Status by Type (2013-2017)

7.3.1 Asia Pacific Biosimilars Sales by Type (2013-2017)

7.3.2 Asia Pacific Biosimilars Revenue by Type (2013-2017)

7.4 Asia Pacific Biosimilars Market Status by Downstream Industry (2013-2017)

CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

8.1 Latin America Biosimilars Market Status by Countries

8.1.1 Latin America Biosimilars Sales by Countries (2013-2017)

8.1.2 Latin America Biosimilars Revenue by Countries (2013-2017)

8.1.3 Brazil Biosimilars Market Status (2013-2017)

8.1.4 Argentina Biosimilars Market Status (2013-2017)

8.1.5 Colombia Biosimilars Market Status (2013-2017)

8.2 Latin America Biosimilars Market Status by Manufacturers

8.3 Latin America Biosimilars Market Status by Type (2013-2017)

8.3.1 Latin America Biosimilars Sales by Type (2013-2017)

8.3.2 Latin America Biosimilars Revenue by Type (2013-2017)

8.4 Latin America Biosimilars Market Status by Downstream Industry (2013-2017)

CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

9.1 Middle East and Africa Biosimilars Market Status by Countries

9.1.1 Middle East and Africa Biosimilars Sales by Countries (2013-2017)

9.1.2 Middle East and Africa Biosimilars Revenue by Countries (2013-2017)

9.1.3 Middle East Biosimilars Market Status (2013-2017)

9.1.4 Africa Biosimilars Market Status (2013-2017)

- 9.2 Middle East and Africa Biosimilars Market Status by Manufacturers
- 9.3 Middle East and Africa Biosimilars Market Status by Type (2013-2017)
 - 9.3.1 Middle East and Africa Biosimilars Sales by Type (2013-2017)
 - 9.3.2 Middle East and Africa Biosimilars Revenue by Type (2013-2017)
- 9.4 Middle East and Africa Biosimilars Market Status by Downstream Industry (2013-2017)

CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF BIOSIMILARS

- 10.1 Global Economy Situation and Trend Overview
- 10.2 Biosimilars Downstream Industry Situation and Trend Overview

CHAPTER 11 BIOSIMILARS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

- 11.1 Production Volume of Biosimilars by Major Manufacturers
- 11.2 Production Value of Biosimilars by Major Manufacturers
- 11.3 Basic Information of Biosimilars by Major Manufacturers
 - 11.3.1 Headquarters Location and Established Time of Biosimilars Major Manufacturer
 - 11.3.2 Employees and Revenue Level of Biosimilars Major Manufacturer
- 11.4 Market Competition News and Trend
 - 11.4.1 Merger, Consolidation or Acquisition News
 - 11.4.2 Investment or Disinvestment News
 - 11.4.3 New Product Development and Launch

CHAPTER 12 BIOSIMILARS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 12.1 Roche
 - 12.1.1 Company profile
 - 12.1.2 Representative Biosimilars Product
 - 12.1.3 Biosimilars Sales, Revenue, Price and Gross Margin of Roche
- 12.2 Amgen
 - 12.2.1 Company profile
 - 12.2.2 Representative Biosimilars Product
 - 12.2.3 Biosimilars Sales, Revenue, Price and Gross Margin of Amgen
- 12.3 AbbVie
 - 12.3.1 Company profile
 - 12.3.2 Representative Biosimilars Product

- 12.3.3 Biosimilars Sales, Revenue, Price and Gross Margin of AbbVie
- 12.4 Sanofi-Aventis
 - 12.4.1 Company profile
 - 12.4.2 Representative Biosimilars Product
 - 12.4.3 Biosimilars Sales, Revenue, Price and Gross Margin of Sanofi-Aventis
- 12.5 Johnson & Johnson
 - 12.5.1 Company profile
 - 12.5.2 Representative Biosimilars Product
 - 12.5.3 Biosimilars Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 12.6 Pfizer
 - 12.6.1 Company profile
 - 12.6.2 Representative Biosimilars Product
 - 12.6.3 Biosimilars Sales, Revenue, Price and Gross Margin of Pfizer
- 12.7 Novo Nordisk
 - 12.7.1 Company profile
 - 12.7.2 Representative Biosimilars Product
 - 12.7.3 Biosimilars Sales, Revenue, Price and Gross Margin of Novo Nordisk
- 12.8 Eli Lilly
 - 12.8.1 Company profile
 - 12.8.2 Representative Biosimilars Product
 - 12.8.3 Biosimilars Sales, Revenue, Price and Gross Margin of Eli Lilly
- 12.9 Novartis
 - 12.9.1 Company profile
 - 12.9.2 Representative Biosimilars Product
 - 12.9.3 Biosimilars Sales, Revenue, Price and Gross Margin of Novartis
- 12.10 Merck
 - 12.10.1 Company profile
 - 12.10.2 Representative Biosimilars Product
 - 12.10.3 Biosimilars Sales, Revenue, Price and Gross Margin of Merck
- 12.11 Sun
 - 12.11.1 Company profile
 - 12.11.2 Representative Biosimilars Product
 - 12.11.3 Biosimilars Sales, Revenue, Price and Gross Margin of Sun
- 12.12 3sbio
 - 12.12.1 Company profile
 - 12.12.2 Representative Biosimilars Product
 - 12.12.3 Biosimilars Sales, Revenue, Price and Gross Margin of 3sbio
- 12.13 Changchun High Tech
 - 12.13.1 Company profile

- 12.13.2 Representative Biosimilars Product
- 12.13.3 Biosimilars Sales, Revenue, Price and Gross Margin of Changchun High Tech
- 12.14 CP Guojian
 - 12.14.1 Company profile
 - 12.14.2 Representative Biosimilars Product
 - 12.14.3 Biosimilars Sales, Revenue, Price and Gross Margin of CP Guojian
- 12.15 Biotech
 - 12.15.1 Company profile
 - 12.15.2 Representative Biosimilars Product
 - 12.15.3 Biosimilars Sales, Revenue, Price and Gross Margin of Biotech
- 12.16 Gelgen
- 12.17 Innovent
- 12.18 Dong Bao
- 12.19 Ganlee
- 12.20 United Laboratories

CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOSIMILARS

- 13.1 Industry Chain of Biosimilars
- 13.2 Upstream Market and Representative Companies Analysis
- 13.3 Downstream Market and Representative Companies Analysis

CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF BIOSIMILARS

- 14.1 Cost Structure Analysis of Biosimilars
- 14.2 Raw Materials Cost Analysis of Biosimilars
- 14.3 Labor Cost Analysis of Biosimilars
- 14.4 Manufacturing Expenses Analysis of Biosimilars

CHAPTER 15 REPORT CONCLUSION

CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE

- 16.1 Methodology/Research Approach
 - 16.1.1 Research Programs/Design
 - 16.1.2 Market Size Estimation
 - 16.1.3 Market Breakdown and Data Triangulation
- 16.2 Data Source

- 16.2.1 Secondary Sources
- 16.2.2 Primary Sources
- 16.3 Reference

I would like to order

Product name: Biosimilars-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

Product link: <https://marketpublishers.com/r/B13EC501C72EN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B13EC501C72EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970